Past Updates from the Clinician Registry Listserv
Update Sent May 31, 2007
NOTE: This document is provided for historical purposes only and may not provide our most accurate and up-to-date information. The most current Clinician's information can be found on the Clinician Home Page.
The following is an update to the current extensively drug resistant tuberculosis (XDR-TB) situation.
If you have any questions on these or other clinical issues, please write to us at coca@cdc.gov.
CDC Letter to Healthcare Providers
Dear Healthcare Professional,
A person with recently diagnosed culture-confirmed, extensively drug-resistant pulmonary tuberculosis (XDR TB) traveled on the following two extended flights (more than 8 hours in duration) in May 2007:
Date From To Airline / Flight#
- May 12/13 Atlanta, Georgia Paris, France Air France #385/Delta #8517
- May 24 Prague, Czech Rep. Montreal, Canada Czech Air #0104
XDR TB is defined as a subtype of multidrug resistant TB (MDR TB) (i.e., an isolate resistant to at least isoniazid and rifampin), with additional resistance to at least two of the most important second-line antibiotics (i.e., a fluoroquinolone and an injectable agent [amikacin, kanamycin, or capreomycin]).
The patient is currently in respiratory isolation in a hospital in the United States, and is receiving medical therapy for XDR TB. He has remained relatively asymptomatic, and his sputum smear results were negative for acid fast bacilli (AFB), both before and after his travel; however, his sputum culture results are positive for XDR TB.
This is the first investigation of a case of XDR TB during air travel. Due to the serious nature of this strain of TB disease, CDC is recommending that all U.S. residents and citizens on these two flights receive evaluation, testing, and follow-up for TB infection.
We are requesting your assistance to perform TB evaluation and testing on any person identified as a contact on one of these flights. The XDR TB Contact Investigation Form is enclosed. Please keep a copy of this completed form for your records, give a copy to the person tested, and also please contact your State or Local TB control office via: http://www.cdc.gov/tb/pubs/tboffices.htm.
For inquiries related to this investigation, please call your State or Local Health Department. For more information about XDR TB, please see this link: http://www.cdc.gov/tb/XDRTB/default.htm.
We greatly appreciate your assistance on this important international XDR TB contact investigation.
Extensively drug resistant TB (XDR-TB) Update
Questions and Answers: XDR TB in TravelerFrom May 30, 2007 CDC Press ConferenceXDR TB Traveler Fact Sheet
Update on CDC Investigation into people potentially exposed to patient with extensively drug-resistant TB
A full transcript of this teleconference is available here: Press Briefing Transcript XDR-TB 5-30-07
CDC is currently investigating a case of extensively drug resistant tuberculosis(XDR TB). The case involves a U.S. citizen with potentially infectious XDR TB who traveled to and from Europe on commercial flights between May 12 and May 24, and then re-entered the U.S. at the Canada-U.S. border via automobile.
Since May 25, the patient has been hospitalized in respiratory isolation and is undergoing additional medical evaluation.
CDC is working with U.S. state and local health departments, International Ministries of Health, the airline industry, and the World Health Organization to notify and follow up passengers and crew who may be at risk for exposure to XDR TB. Each country involved in the investigation is determining guidance for its own residents.
Persons who were on one of the following airline flights:
- Air France #385 /Delta # 8517 departing Atlanta 5/12, arriving Paris 5/13
- Czech Air # 0140 departing Prague and arriving Montreal 5/24
should be instructed to call one of the following numbers and inform them oftheir possible exposure:
1-800-CDC-INFO (1-800-232-4636)
or
the CDC Operations Center at 770.488.7100
For the latest information on this event, please refer to the following CDC web pages:
http://www.cdc.gov/tb/xdrtb/default.htm & http://www.cdc.gov/tb/default.htm
Please visit the COCA web page for additional information: http://www.bt.cdc.gov/coca/.
Our Clinician Communication Team is committed to excellence in reporting our weekly updates. Please e-mail coca@cdc.gov should you note any written errors or discrepancies.
If you need to unsubscribe or update your information, please go to our website: http://www.bt.cdc.gov/clinregistry
If you need further information or technical help, please send an e-mail message to: coca@cdc.gov
Page last modified May 31, 2007
Content Source:
- Coordinating Center for Health Information and Service (CCHIS)
National Center for Health Marketing (NCHM)
Division of Health Communication and Marketing (DHCM)
Emergency Communication System (ECS)